Abstract Glucocorticoids (GCs) have potent anti-inflammatory and immunomodulating effects, making them effective for treating various diseases. They are among the most commonly prescribed medications worldwide. The prevalence of GC therapy in the general population is estimated to be ∼0.9 to 3%, though it is challenging to determine precisely. The chronic GC therapy is associated with severe morbidity and increased mortality due to iatrogenic Cushing's syndrome and suppression of the hypothalamic–pituitary–adrenal axis, leading to tertiary adrenal insufficiency. Therefore, it is not recommended to abruptly stop chronic GC therapy, and a gradual tapering of GCs is generally considered the ideal approach for GCs withdrawal. However, withdrawing GCs in patients on chronic therapy can be challenging due to the difficulty in accurately assessing HPA function. In this article, we aim to provide a practical, case-based approach to GC withdrawal based on current literature and our extensive experience in this field.
{"title":"Safely Withdrawing Glucocorticoid Therapy: A Case-Based Approach","authors":"Mohammed Alenazi, Khaled A Aldahmani, S. Imran","doi":"10.1055/s-0044-1788035","DOIUrl":"https://doi.org/10.1055/s-0044-1788035","url":null,"abstract":"Abstract Glucocorticoids (GCs) have potent anti-inflammatory and immunomodulating effects, making them effective for treating various diseases. They are among the most commonly prescribed medications worldwide. The prevalence of GC therapy in the general population is estimated to be ∼0.9 to 3%, though it is challenging to determine precisely. The chronic GC therapy is associated with severe morbidity and increased mortality due to iatrogenic Cushing's syndrome and suppression of the hypothalamic–pituitary–adrenal axis, leading to tertiary adrenal insufficiency. Therefore, it is not recommended to abruptly stop chronic GC therapy, and a gradual tapering of GCs is generally considered the ideal approach for GCs withdrawal. However, withdrawing GCs in patients on chronic therapy can be challenging due to the difficulty in accurately assessing HPA function. In this article, we aim to provide a practical, case-based approach to GC withdrawal based on current literature and our extensive experience in this field.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":" 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141678339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tabarak Haamid Elbo-Iswadi, H. Alsharayri, Rahaf Wardeh, A. Bashier, Fauzia Rashid, Elamin Ibrahim Abdelgadir
Introduction Cardiovascular disease is a leading cause of mortality in people with diabetes (PWD). We aimed to explore the role of troponin T (TnT) and probrain natriuretic peptide (proBNP) as screening and prognostic indicators of cardiovascular morbidity and mortality in PWD in the existing literature. Methods This review paper is a focused narrative nonsystematic review of the literature which examined relevant publications pertinent to the significance of cardiac biomarkers. We aimed to investigate the diagnostic value of cardiac TnT (cTnT) and cTnI in addition to proBNP in diabetes and the prognostic value of cTnT and proBNP in diabetic and nondiabetic patients. The process of searching through literature was conducted from December 2022 to April 2023. Searches were done across PubMed and Google Scholar databases to identify relevant articles published from January 2001 to April 2023. The selected were entered into EndNote 20 software to extract the title and abstract. Results A total of 75 articles were identified in Google Scholar in addition to 32 articles from PubMed. After a thorough review, only a total of 22 articles were selected, pointing out those which discussed the pathophysiology and diagnostic, prognostic, and screening values of the types of Tn and proBNP markers. The value of TnT in PWD, specifically T2D, is threefold higher than in healthy patients. Individuals with high levels of high-sensitivity (hs) cTnI or cTnT were at the highest mortality risk. Nonetheless, N-terminal (NT)-proBNP and TnT function independently as predictors of unfavorable outcomes. Conclusions TnT is an important early screening tool prognostic indicator. Elevated TnT was associated with an increased risk of cardiovascular events in PWD. hs-cTn may help diabetes-related clinical care for older persons by identifying those at high mortality risk; furthermore, in diabetic individuals, NT-pro-BNP appears to be 92% sensitive and 90% specific for the diagnosis of heart failure.
{"title":"Review of the Diagnostic and Prognostic Values of Cardiac Markers in Diabetes","authors":"Tabarak Haamid Elbo-Iswadi, H. Alsharayri, Rahaf Wardeh, A. Bashier, Fauzia Rashid, Elamin Ibrahim Abdelgadir","doi":"10.1055/s-0044-1786014","DOIUrl":"https://doi.org/10.1055/s-0044-1786014","url":null,"abstract":"\u0000 Introduction Cardiovascular disease is a leading cause of mortality in people with diabetes (PWD). We aimed to explore the role of troponin T (TnT) and probrain natriuretic peptide (proBNP) as screening and prognostic indicators of cardiovascular morbidity and mortality in PWD in the existing literature.\u0000 Methods This review paper is a focused narrative nonsystematic review of the literature which examined relevant publications pertinent to the significance of cardiac biomarkers. We aimed to investigate the diagnostic value of cardiac TnT (cTnT) and cTnI in addition to proBNP in diabetes and the prognostic value of cTnT and proBNP in diabetic and nondiabetic patients. The process of searching through literature was conducted from December 2022 to April 2023. Searches were done across PubMed and Google Scholar databases to identify relevant articles published from January 2001 to April 2023. The selected were entered into EndNote 20 software to extract the title and abstract.\u0000 Results A total of 75 articles were identified in Google Scholar in addition to 32 articles from PubMed. After a thorough review, only a total of 22 articles were selected, pointing out those which discussed the pathophysiology and diagnostic, prognostic, and screening values of the types of Tn and proBNP markers. The value of TnT in PWD, specifically T2D, is threefold higher than in healthy patients. Individuals with high levels of high-sensitivity (hs) cTnI or cTnT were at the highest mortality risk. Nonetheless, N-terminal (NT)-proBNP and TnT function independently as predictors of unfavorable outcomes.\u0000 Conclusions TnT is an important early screening tool prognostic indicator. Elevated TnT was associated with an increased risk of cardiovascular events in PWD. hs-cTn may help diabetes-related clinical care for older persons by identifying those at high mortality risk; furthermore, in diabetic individuals, NT-pro-BNP appears to be 92% sensitive and 90% specific for the diagnosis of heart failure.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"76 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140984749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diabetes, Kidneys, Heart, and Ramadan","authors":"S. Beshyah","doi":"10.1055/s-0044-1786190","DOIUrl":"https://doi.org/10.1055/s-0044-1786190","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"2012 29","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141027352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. N. R. Bondugulapati, Rita Nawar, Hussam Abusahmin, Rahat Ghazanfar, S. Beshyah
Abstract The Fifth United Arab Emirates Obesity Conference was held from November 4 to 5, 2023, in Dusit Thani, Abu Dhabi, UAE. The theme of the conference was “What can we do better in obesity management?” The program included several didactic lectures and a question-and-answer time separately or grouped thematically. Over 2 days, the speakers covered the burden, definitions, and evaluation of obesity, including uncommon chromosomal and genetic syndromes associated with obesity in appropriate cases. It highlighted the importance of policy changes for public health improvement and prevention of obesity, the role of multidisciplinary teams in managing persons with obesity holistically, and present and future therapies, including personalized precision medicine backed up by science.
{"title":"The Fifth United Arab Emirates Obesity Conference, November 4–5, 2023, Abu Dhabi, UAE","authors":"L. N. R. Bondugulapati, Rita Nawar, Hussam Abusahmin, Rahat Ghazanfar, S. Beshyah","doi":"10.1055/s-0043-1777357","DOIUrl":"https://doi.org/10.1055/s-0043-1777357","url":null,"abstract":"Abstract The Fifth United Arab Emirates Obesity Conference was held from November 4 to 5, 2023, in Dusit Thani, Abu Dhabi, UAE. The theme of the conference was “What can we do better in obesity management?” The program included several didactic lectures and a question-and-answer time separately or grouped thematically. Over 2 days, the speakers covered the burden, definitions, and evaluation of obesity, including uncommon chromosomal and genetic syndromes associated with obesity in appropriate cases. It highlighted the importance of policy changes for public health improvement and prevention of obesity, the role of multidisciplinary teams in managing persons with obesity holistically, and present and future therapies, including personalized precision medicine backed up by science.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"17 1","pages":"149 - 152"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139325496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Journal of Diabetes and Endocrine Practice (2018–2023): A Quest for a Role!","authors":"S. Beshyah","doi":"10.1055/s-0043-1777358","DOIUrl":"https://doi.org/10.1055/s-0043-1777358","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"62 1","pages":"147 - 148"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139327798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Alessa, W. Hussein, B. Afandi, Ali Al Reesi, Naji Aljohani
These are the abstracts of the Clinical Congress of the Gulf Association of Endocrinology and Diabetes (GAED) held on October 19 – 21, 2023. 1,2 The educational objective of the congress was to give a “ state of the art in endocrine practice. ” The programs included plenary symposia, delivered by international and regional keyopinion leaders. In addition, free communications on current research and clinical practice within and beyond the Gulf region were presented as oral presentations and posters. We present here the abstracts of these free communications after minimal restyling and editing to suit the publication requirements of the journal. We hope that by publishing them in our open-access journal, we provide early recognition of the work and extend the bene fi t to those who could not make it to the live presentations similar to our previous conferences. 3 – 6 We also hope to stimulate networking between parties of mutual research interests.
{"title":"Free Communications of the Gulf Association of Endocrinology and Diabetes Annual Congress 2023, Muscat, Oman, October 19–21, 2023","authors":"T. Alessa, W. Hussein, B. Afandi, Ali Al Reesi, Naji Aljohani","doi":"10.1055/s-0043-1777328","DOIUrl":"https://doi.org/10.1055/s-0043-1777328","url":null,"abstract":"These are the abstracts of the Clinical Congress of the Gulf Association of Endocrinology and Diabetes (GAED) held on October 19 – 21, 2023. 1,2 The educational objective of the congress was to give a “ state of the art in endocrine practice. ” The programs included plenary symposia, delivered by international and regional keyopinion leaders. In addition, free communications on current research and clinical practice within and beyond the Gulf region were presented as oral presentations and posters. We present here the abstracts of these free communications after minimal restyling and editing to suit the publication requirements of the journal. We hope that by publishing them in our open-access journal, we provide early recognition of the work and extend the bene fi t to those who could not make it to the live presentations similar to our previous conferences. 3 – 6 We also hope to stimulate networking between parties of mutual research interests.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"74 4 1","pages":"155 - 197"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139329099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Gulf Association of Endocrinology and Diabetes in 2023: A Message from the President and Officers","authors":"Ali Al Mamari, Naji Aljohani, Tarik AlHadd","doi":"10.1055/s-0043-1777268","DOIUrl":"https://doi.org/10.1055/s-0043-1777268","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"255 1","pages":"153 - 154"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139326059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Introduction Since insulin analogs have pharmacological properties that are similar to the normal physiological action of insulin, it has been suggested that they provide better glucose control and less rates of hypoglycemia compared to human insulins. Methods We performed a narrative, nonsystematic review of the literature including clinical trials, systematic reviews, meta-analyses, and professional guidelines related to the comparison of human insulins and insulin analogs in terms of glucose control, safety profile, and cost. Results Long-acting basal insulins result in mild improvement in glucose control and less rates of nocturnal hypoglycemic compared to neutral protamine Hagedorn insulin, mainly among patients with type 1 diabetes. Rapid-acting insulin analogs provide better glucose control and lower rates of hypoglycemia compared to regular insulin among patients with type 1 diabetes, whereas no advantage has been shown for insulin analogs among patients with type 2 diabetes for glucose control or hypoglycemia. Premixed insulin analogs provided no advantage in glucose control and inconsistent benefit in lowering the rates of hypoglycemia compared to human premixed insulins among patients with type 2 diabetes. The cost of insulin analogs is significantly higher than human insulins, and favorable cost-effectiveness has only been demonstrated for rapid-acting insulin analogs in type 1 diabetes. Conclusion Currently available evidence supports the use of rapid-acting insulin analogs and possibly long-acting basal insulin over human insulins for patients with type 1 diabetes. For patients with type 2 diabetes, the use of long-acting insulin analogs may be recommended for selected patients who are at an increased risk of significant hypoglycemia, while no clear benefits of meal insulin analogs over human insulins have been observed.
{"title":"Comparison of Insulin Analogs and Human Insulins: A Narrative Review","authors":"M. Eledrisi, M. Danjuma","doi":"10.1055/s-0043-1771027","DOIUrl":"https://doi.org/10.1055/s-0043-1771027","url":null,"abstract":"Abstract Introduction Since insulin analogs have pharmacological properties that are similar to the normal physiological action of insulin, it has been suggested that they provide better glucose control and less rates of hypoglycemia compared to human insulins. Methods We performed a narrative, nonsystematic review of the literature including clinical trials, systematic reviews, meta-analyses, and professional guidelines related to the comparison of human insulins and insulin analogs in terms of glucose control, safety profile, and cost. Results Long-acting basal insulins result in mild improvement in glucose control and less rates of nocturnal hypoglycemic compared to neutral protamine Hagedorn insulin, mainly among patients with type 1 diabetes. Rapid-acting insulin analogs provide better glucose control and lower rates of hypoglycemia compared to regular insulin among patients with type 1 diabetes, whereas no advantage has been shown for insulin analogs among patients with type 2 diabetes for glucose control or hypoglycemia. Premixed insulin analogs provided no advantage in glucose control and inconsistent benefit in lowering the rates of hypoglycemia compared to human premixed insulins among patients with type 2 diabetes. The cost of insulin analogs is significantly higher than human insulins, and favorable cost-effectiveness has only been demonstrated for rapid-acting insulin analogs in type 1 diabetes. Conclusion Currently available evidence supports the use of rapid-acting insulin analogs and possibly long-acting basal insulin over human insulins for patients with type 1 diabetes. For patients with type 2 diabetes, the use of long-acting insulin analogs may be recommended for selected patients who are at an increased risk of significant hypoglycemia, while no clear benefits of meal insulin analogs over human insulins have been observed.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128449192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khadija Hafidh, Tawfik A. Besheya, R. Elmehdawi, S. Beshyah
Abstract Objectives The literature on the impact of Ramadan fasting (RF) on metabolic control and health in people with diabetes is widely spread in many journals making it not readily accessible to those interested in the subject. We aimed to provide a narrative overview of the global literature production in 1 year (2022) on diabetes and RF. Materials and Methods It is a narrative, non-systematic review of the international literature from a single major medical online database (i.e., PubMed) in one calendar year (2022). Relevant literature was narrated in a concise thematic account. Results Themes emerged from the review of the literature on RF published in 2022, including a couple of studies on the epidemiology of fasting in the real world by adults and children. Three studies involved some pathophysiological observations of metabolic and other biochemical markers. Several studies assessed the use and safety of different pharmacological therapeutic agents. Certain sulfonylureas, such as modified-release gliclazide, were considered safer than other sulfonylureas. Newer basal insulin analogs were studied in different geographical and socioeconomic settings (Gulf vs. South East Asia). The role of diabetes technology in Ramadan was the focus of several studies of insulin pumps and monitoring. Special themes were high-risk groups, pregnancy, acute complications, postbariatric surgery, and COVID-19 in Ramadan. Few studies examined the safety of sodium-glucose co-transporter-2 inhibitors as a class and individually during RF. Professional and patient perspectives released in 2022 included updated guidelines for adults and adolescents. Conclusion In 2022's medical literature, RF and diabetes continue to address epidemiology, the burden of diabetes care on fasting patients, and discussions of concerns of patients and healthcare professionals. Risk stratification and issues of high-risk patients are still in focus for children, adolescents, and adults. Approaches to effective management still gather evidence for newer pharmacological agents and diabetes technology.
{"title":"Ramadan Fasting and Diabetes (2022): The Year in Review","authors":"Khadija Hafidh, Tawfik A. Besheya, R. Elmehdawi, S. Beshyah","doi":"10.1055/s-0043-1764458","DOIUrl":"https://doi.org/10.1055/s-0043-1764458","url":null,"abstract":"Abstract Objectives The literature on the impact of Ramadan fasting (RF) on metabolic control and health in people with diabetes is widely spread in many journals making it not readily accessible to those interested in the subject. We aimed to provide a narrative overview of the global literature production in 1 year (2022) on diabetes and RF. Materials and Methods It is a narrative, non-systematic review of the international literature from a single major medical online database (i.e., PubMed) in one calendar year (2022). Relevant literature was narrated in a concise thematic account. Results Themes emerged from the review of the literature on RF published in 2022, including a couple of studies on the epidemiology of fasting in the real world by adults and children. Three studies involved some pathophysiological observations of metabolic and other biochemical markers. Several studies assessed the use and safety of different pharmacological therapeutic agents. Certain sulfonylureas, such as modified-release gliclazide, were considered safer than other sulfonylureas. Newer basal insulin analogs were studied in different geographical and socioeconomic settings (Gulf vs. South East Asia). The role of diabetes technology in Ramadan was the focus of several studies of insulin pumps and monitoring. Special themes were high-risk groups, pregnancy, acute complications, postbariatric surgery, and COVID-19 in Ramadan. Few studies examined the safety of sodium-glucose co-transporter-2 inhibitors as a class and individually during RF. Professional and patient perspectives released in 2022 included updated guidelines for adults and adolescents. Conclusion In 2022's medical literature, RF and diabetes continue to address epidemiology, the burden of diabetes care on fasting patients, and discussions of concerns of patients and healthcare professionals. Risk stratification and issues of high-risk patients are still in focus for children, adolescents, and adults. Approaches to effective management still gather evidence for newer pharmacological agents and diabetes technology.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134057650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Bashir, Tania Jabir, M. Z. Haq, M. Mokhtar, H. Surchi, Gowri Karuppasamy, Khaled M Dukhan
Abstract These are the abstracts of the free communications of The Seventh Qatar Diabetes, Endocrinology, and Metabolic Conference, Doha, Qatar, March 2–4, 3–5, 2023. The QDEM-7 was a hybrid conference. The declared educational objectives of the congress were to give a “state of the art in endocrine practice.” International and regional key opinion leaders delivered plenary and symposia presentations. In addition, free communications on current research and clinical practice in the region and worldwide were presented . We present here the abstracts of the congress as submitted by the authors of the free communications after minimal restyling and editing to suit the publication requirements of the Journal. We hope that by publishing them in our open-access Journal, we provide early recognition of the work and extend the benefit to those who could not make it to the live presentations.
{"title":"Free Communications of The Seventh Qatar Diabetes, Endocrinology, and Metabolic Conference, Doha, Qatar, March 2–4, 3–5, 2023","authors":"M. Bashir, Tania Jabir, M. Z. Haq, M. Mokhtar, H. Surchi, Gowri Karuppasamy, Khaled M Dukhan","doi":"10.1055/s-0043-1768976","DOIUrl":"https://doi.org/10.1055/s-0043-1768976","url":null,"abstract":"Abstract These are the abstracts of the free communications of The Seventh Qatar Diabetes, Endocrinology, and Metabolic Conference, Doha, Qatar, March 2–4, 3–5, 2023. The QDEM-7 was a hybrid conference. The declared educational objectives of the congress were to give a “state of the art in endocrine practice.” International and regional key opinion leaders delivered plenary and symposia presentations. In addition, free communications on current research and clinical practice in the region and worldwide were presented . We present here the abstracts of the congress as submitted by the authors of the free communications after minimal restyling and editing to suit the publication requirements of the Journal. We hope that by publishing them in our open-access Journal, we provide early recognition of the work and extend the benefit to those who could not make it to the live presentations.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"112 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128643568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：